AMAG Pharmaceuticals Inc $ 10.55 0.51 (5.08%)
Volume:
376,120
Avg Vol (1m):
546,338
Market Cap $:
361.58 Mil
Enterprise Value $:
541.37 Mil
P/E (TTM):
0.00
P/B:
1.37
Financial Strength | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.41 | ||
| Equity-to-Asset | 0.35 | ||
| Debt-to-Equity | 1.16 | ||
| Debt-to-EBITDA | -0.98 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | -2.42 | ||
| Beneish M-Score | -2.59 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -35.97 | ||
| Net Margin % | -115.05 | ||
| ROE % | -85.99 | ||
| ROA % | -40.02 | ||
| ROC (Joel Greenblatt) % | -1738.1 | ||
| 3-Year Revenue Growth Rate | -8.1 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 1.37 | ||
| PS Ratio | 1.1 | ||
| EV-to-EBIT | -1.55 | ||
| EV-to-EBITDA | -1.74 | ||
| EV-to-Revenue | 1.67 | ||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.37 | ||
| Days Inventory | 96.01 | ||
| Days Sales Outstanding | 121.23 | ||
| Days Payable | 53.33 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 0.6 | ||
| Price-to-Median-PS-Value | 0.25 | ||
| Earnings Yield (Greenblatt) % | -63.66 | ||
| Forward Rate of Return (Yacktman) % | -10.78 |